Literature DB >> 24659498

Dystrophic mdx mice develop severe cardiac and respiratory dysfunction following genetic ablation of the anti-inflammatory cytokine IL-10.

Yuko Nitahara-Kasahara1, Hiromi Hayashita-Kinoh1, Tomoko Chiyo1, Akiyo Nishiyama1, Hironori Okada1, Shin'ichi Takeda1, Takashi Okada2.   

Abstract

Duchenne muscular dystrophy (DMD) is a progressive muscle-wasting disease that causes respiratory and cardiac failure. Inflammation is a key pathological characteristic of dystrophic muscle lesion formation, but its role and regulation in the disease time course has not been sufficiently examined. In the present study, we used IL-10(-/-)/mdx mice lacking both dystrophin and the anti-inflammatory cytokine, interleukin-10 (IL-10), to investigate whether a predisposition to inflammation affects the severity of DMD with advancing age. The IL-10 deficiency caused a profound DMD phenotype in the dystrophic heart such as muscle degeneration and extensive myofiber loss, but the limb muscle and diaphragm morphology of IL-10(-/) (-)/mdx mice was similar to that of mdx mice. Extensive infiltrates of pro-inflammatory M1 macrophages in regeneration of cardiotoxin-injured muscle, altered M1/M2 macrophage phenotype and increased pro-inflammatory cytokines/chemokines production were observed in the diaphragm and heart of IL-10(-/-)/mdx mice. We characterized the IL-10(-/-)/mdx mice as a dystrophic model with chronic inflammation and severe cardiorespiratory dysfunction, as evidenced by decreased percent fractional shortening (%FS) and ejection fraction percent (EF%) on echocardiography, reduced lower tidal volume on whole-body plethysmography. This study suggests that a predisposition to inflammation is an important indicator of DMD disease progression. Therefore, the development of anti-inflammatory strategies may help in slowing down the cardiorespiratory dysfunction on DMD.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659498     DOI: 10.1093/hmg/ddu113

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.

Authors:  D Sharma; R Al-Khalidi; S Edgar; Q An; Y Wang; C Young; D Nowis; D C Gorecki
Journal:  Gene Ther       Date:  2016-12-22       Impact factor: 5.250

2.  Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient mice.

Authors:  Rui Xu; Neha Singhal; Yelda Serinagaoglu; Kumaran Chandrasekharan; Mandar Joshi; John A Bauer; Paulus M L Janssen; Paul T Martin
Journal:  Am J Pathol       Date:  2015-10       Impact factor: 4.307

3.  Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Subha V Raman; Kan N Hor; Wojciech Mazur; Nancy J Halnon; John T Kissel; Xin He; Tam Tran; Suzanne Smart; Beth McCarthy; Michael D Taylor; John L Jefferies; Jill A Rafael-Fortney; Jeovanna Lowe; Sharon L Roble; Linda H Cripe
Journal:  Lancet Neurol       Date:  2014-12-30       Impact factor: 44.182

4.  Sunitinib inhibits STAT3 phosphorylation in cardiac muscle and prevents cardiomyopathy in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Ariany Oliveira-Santos; Marisela Dagda; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2022-07-21       Impact factor: 5.121

Review 5.  Small mammalian animal models of heart disease.

Authors:  Paula Camacho; Huimin Fan; Zhongmin Liu; Jia-Qiang He
Journal:  Am J Cardiovasc Dis       Date:  2016-09-15

Review 6.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

7.  TAZ Activator Is Involved in IL-10-Mediated Muscle Responses in an Animal Model of Traumatic Brain Injury.

Authors:  Ruyi Zou; Da Li; Gang Wang; Mo Zhang; Yili Zhao; Zeyu Yang
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

8.  The FVB Background Does Not Dramatically Alter the Dystrophic Phenotype of Mdx Mice.

Authors:  Nalinda B Wasala; Keqing Zhang; Lakmini P Wasala; Chady H Hakim; Dongsheng Duan
Journal:  PLoS Curr       Date:  2015-02-10

9.  Dystrophin Deficiency Causes Progressive Depletion of Cardiovascular Progenitor Cells in the Heart.

Authors:  Sarka Jelinkova; Yvonne Sleiman; Petr Fojtík; Franck Aimond; Amanda Finan; Gerald Hugon; Valerie Scheuermann; Deborah Beckerová; Olivier Cazorla; Marie Vincenti; Pascal Amedro; Sylvain Richard; Josef Jaros; Petr Dvorak; Alain Lacampagne; Gilles Carnac; Vladimir Rotrekl; Albano C Meli
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 10.  Caenorhabditis elegans as a Model System for Duchenne Muscular Dystrophy.

Authors:  Rebecca A Ellwood; Mathew Piasecki; Nathaniel J Szewczyk
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.